SCHEMBL19639788

SCHEMBL19639788

CCC(=O)NNc1cccc(C(F)(F)F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.57
HPGD P15428 1/20 0.57
SMN1; SMN2 Q16637 4/20 0.56
MAPT P10636 8/20 0.55
GAA P10253 5/20 0.55
ATM Q13315 2/20 0.55
ALOX12 P18054 1/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
NPSR1 Q6W5P4 3/20 0.55
XBP1 P17861 1/20 0.55
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
POLB P06746 2/20 0.53
TP53 P04637 1/20 0.52
HTT P42858 2/20 0.51
RAB9A P51151 1/20 0.51
RXFP1 Q9HBX9 2/20 0.51
CYP2D6 P10635 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2184782 0.84 SMN1; SMN2 (0.71) ALDH1A1SMN1; SMN2MAPTGAAMEN1
SCHEMBL30977690 0.84 SMN1; SMN2 (0.71) ALDH1A1SMN1; SMN2MAPTGAAMEN1
SCHEMBL20984529 0.82 MAPT (0.58) ALDH1A1HPGDMAPTGAAMEN1
SCHEMBL15541465 0.81 MAPT (0.61) ALDH1A1HPGDSMN1; SMN2MAPTGAA
SCHEMBL28191918 0.81 GAA (0.62) ALDH1A1SMN1; SMN2MAPTGAAMEN1
SCHEMBL11798167 0.80 KIF11 (0.61) ALDH1A1HPGDSMN1; SMN2MAPTGAA
SCHEMBL2199062 0.80 MAPT (0.56) ALDH1A1HPGDSMN1; SMN2MAPTGAA
SCHEMBL9525972 0.79 GAA (0.54) ALDH1A1SMN1; SMN2GAAMEN1KMT2A
SCHEMBL15540945 0.77 RXFP1 (0.62) ALDH1A1HPGDSMN1; SMN2MAPTGAA
SCHEMBL2925587 0.76 MAPT (0.58) ALDH1A1SMN1; SMN2MAPTGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464269-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A HNE RELATED DISEASE CHIESI FARM SPA (IT) 2020-04-01 EP disclosed
WO-2017207433-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED CHIESI FARMACEUTICI S.P.A. (IT) 2018-03-01 WO disclosed
US-9862706-B2 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2018-01-09 US disclosed
US-9862706-B2 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2018-01-09 US disclosed
WO-2017207433-A1 HETETOCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED CHIESI FARMACEUTICI S.P.A. (IT) 2017-12-07 WO disclosed
US-20170342056-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed
US-20170342056-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed
US-20170342056-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342056-A1 NOVEL COMPOUNDS SERPINB1, ELANE, MPO ALDH1A1 98/4885HPGD 26/4885SMN1; SMN2 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.